Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$60.50
$0.14(0.27%)
At close: 4:00 PM EDT
$60.50
$0.14(0.27%)
Day’s Range― - ―
52-Week Range$14.79 - $62.32
Previous Close$53
Volume368.77K
Average Volume (3M)1.11M
Market Cap
$3.62B
Enterprise Value$2.46K
Total Cash (Recent Filing)$895.15M
Total Debt (Recent Filing)$1.51M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 18, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding73,270,760
10 Day Avg. Volume1,699,445
30 Day Avg. Volume1,107,220
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$73.90Price Target Upside22.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.82
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces financial risk and avoids a heavy interest burden while Enliven funds clinical development. This gives management greater flexibility to allocate capital toward research, trials, and pipeline advancement, and provides more resilience than a similarly unprofitable biotech carrying substantial leverage.
Improved CapitalizationThe substantial increase in total assets indicates that Enliven has strengthened its capitalization relative to prior years. A larger asset base can support ongoing research and clinical programs, extend operational capacity, and provide a stronger foundation for executing development plans over the next several quarters.
Precision Oncology PipelineA pipeline focused on genetically defined oncology targets can support a differentiated development strategy by concentrating resources on biologically specified patient groups. Selective kinase inhibitors designed to improve tolerability may also enhance the clinical value proposition if development results validate the intended profile.
Bears Say
No Product RevenueWith no marketed products or established recurring revenue, Enliven cannot currently fund operations through customer sales. Its financial outlook therefore remains dependent on successful clinical development and future commercialization, licensing, or collaboration opportunities rather than an existing revenue-generating business.
Persistent Net LossesExpanding losses show that operating investment continues to rise without corresponding commercial income. Persistent negative earnings reduce visibility into a path toward profitability and may require management to maintain substantial spending for research and trials before the pipeline can generate any economic return.
Ongoing Cash BurnContinued negative operating and free cash flow means Enliven is consuming cash to sustain research and operations rather than generating internal funding. Even with low leverage, reliance on external financing can dilute shareholders or constrain development plans if capital availability becomes less favorable.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics’s price range in the past 12 months?
Enliven Therapeutics lowest stock price was $14.79 and its highest was $62.32 in the past 12 months.
What is Enliven Therapeutics’s market cap?
Enliven Therapeutics’s market cap is $3.62B.
When is Enliven Therapeutics’s upcoming earnings report date?
Enliven Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 58 days.
How were Enliven Therapeutics’s earnings last quarter?
Enliven Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.387 by -$0.103.
Is Enliven Therapeutics overvalued?
According to Wall Street analysts Enliven Therapeutics’s price is currently Undervalued.
Does Enliven Therapeutics pay dividends?
Enliven Therapeutics does not currently pay dividends.
What is Enliven Therapeutics’s EPS estimate?
Enliven Therapeutics’s EPS estimate is -0.43.
How many shares outstanding does Enliven Therapeutics have?
Enliven Therapeutics has 73,270,760 shares outstanding.
What happened to Enliven Therapeutics’s price movement after its last earnings report?
Enliven Therapeutics reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.387. Following the earnings report the stock price went up 0.955%.
Which hedge fund is a major shareholder of Enliven Therapeutics?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.90 (22.15% Upside)
$73.90 (22.15% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 75%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 261.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
80.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enliven Therapeutics
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$73.90
▲(22.15% Upside)
Technical Analysis
Crispr Therapeutics AG
―
IDEAYA Biosciences
―
Legend Biotech
―
Relay Therapeutics
―
Tango Therapeutics
―
Ownership Overview
22.52% Insiders
13.90% Mutual Funds
8.00% Other Institutional Investors
46.03% Public Companies and
Individual Investors